• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

SubjectWell Expands Its Clinical Trials Marketplace to United Kingdom, Ireland, and South Africa

Share:

January 14, 2020

Highlights on this story:
  • SubjectWell announced it is expanding its risk-free clinical trials marketplace into the United Kingdom, Ireland and South Africa.
  • – With 86% of clinical trials operating sites outside of the U.S., the company continues to develop a more streamlined and complete risk-free patient recruitment offering, now with global reach.

SubjectWell, an Austin, TX-based risk-free clinical trials marketplace announced it has expanded its patient recruitment services into the United Kingdom, Ireland, and South Africa. Supplementing its current footprint in the U.S. and Canada, the expansion is part of SubjectWell’s efforts to meet the needs of its pharmaceutical and clinical trial sponsors running global clinical trials, all while continuing to accelerate last patient in (LPI) by increasing awareness of clinical research in the general population and only charging for those patients who randomize.

Meeting Regulatory Framework

Additionally, SubjectWell has met regulatory framework by complying with the specific requirements for any information collected, such as the requirements of the EU General Data Protection Regulation (GDPR), ensuring that personal data is gathered with clear disclosures and under strict conditions, protecting businesses and patients alike.

Founded in 2012, SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize. Unlike traditional approaches to recruiting which are study, site and disease-specific, SubjectWell’s technology continuously recruits nationwide, informing and educating patients about clinical trials in general, at times when they are not thinking about their condition. We then contact and qualify these patients as new trials are added to our marketplace.

2020 International Market Expansion Plans

SubjectWell will continue to expand into additional international markets in 2020, strengthening its commitment to serving as a single partner and offering global services to its contract research organizations and sponsors.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Smith+Nephew Acquires Novel Cementless Partial Knee SystemSmith+Nephew Acquires Novel Cementless Partial Knee System
  • U.S. Telemedicine App Downloads Spikes During COVID-19 PandemicU.S. Telemedicine App Downloads Spikes During COVID-19 Pandemic
  • Indian Digital Therapeutics Firm Launches COVID-19 Recovery Programme for Diabetic PatientsIndian Digital Therapeutics Firm Launches COVID-19 Recovery Programme for Diabetic Patients
  • Precision medicine player joins Biden Cancer Initiative aiming to improve clinical trials accessPrecision medicine player joins Biden Cancer Initiative aiming to improve clinical trials access
  • LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen PharmaLGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma
  • Sverica Capital Management Announces Acquisition of Gener8, LLCSverica Capital Management Announces Acquisition of Gener8, LLC
  • Garmin ® Introduces the Venu GPS Smartwatch with Stunning AMOLED DisplayGarmin ® Introduces the Venu GPS Smartwatch with Stunning AMOLED Display
  • Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in CashLigand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications